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Abstract
Background: Artesunate is a commonly used antimalarial drug derived from artemisinin. It is
rapidly converted to dihydroartemisinin. Little is known on this conversion in the GI tract and
blood, and how this influences absorption. In order to study the absorption phase of the kinetics
of artesunate following oral administration in rats, samples were collected at baseline, and then 0.5,
2, 5, 10, 15, 30, 45, 60 and 120 minutes after a single dose of 150 mg.
Results: Peak concentration of parent artesunate and dihydroartemisinin was achieved within 5
and 37.5 +/- 8.7 min, respectively of start of administration through gavage. The half lives of
absorption were 2.73 +/- 0.85 and 12.49 +/- 2.49 min, respectively.
Conclusions: These times were considerably shorter for artesunate than those found in studies
which start sampling later. The profiles of parent compound and metabolite result from a complex
equation dictated by the pH-dependent rates of hydroxylation of artesunate to dihydroartemisinin,
the different rates at which either compounds are absorbed, and the catalytic hydroxylation by
esterases. The rate of chemical oxidation of artesunate is pH dependent; this explains its rapid
conversion to dihydroartemisinin in the stomach, as compared to its greater stability in other
compartments at higher pH and in plasma. We propose that variable proportions of absorption
take place in the stomach, and conclude that parent artesunate reaches an early peak within
minutes of dosing, and that the early dihydroartemisinin levels result primarily from the absorption
of the metabolite as such.
Background
Artesunate, dihydroarteminsinin -10α  – hemisuccinate, is
a semi-synthetic derivative of artemisinin which is used
for the treatment of both uncomplicated and severe ma-
laria. It is formulated for oral, parenteral (intramuscular
and intravenous) and rectal administration and used clin-
ically worldwide. Because of rapid hydrolysis to dihy-
droartemisinin (also referred to as artenimol), artesunate
is considered by many as a prodrug of the latter (for re-
view see Navaratnam et al [1]).
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Current knowledge of the absorption phase after oral ad-
ministration is incomplete. We have established that
artesunate stability varies as a function of pH and temper-
ature. This transformation of artesunate to dihydroartem-
isinin follows pseudo-first order kinetics at constant
temperature; as a result, in the stomach at pH 1.2 artesu-
nate is short-lived (tl/2 = 10.3 minutes), whilst at neutral
pH its half life is significantly longer (tl/2 = 7.3 hours in
plasma) (unpublished data; manuscript in preparation).
Esterases too play a role in the oxidation of artesunate [2].
It is therefore not surprising that pharmacokinetic studies
that start sampling too late after dosing may fail to detect
artesunate.
Therefore, we conducted a study with intense, early sam-
pling focusing on the absorption phase after oral intake.
This investigation describes the pharmacokinetics of
artesunate and its metabolite dihydroartemisinin in rats
following a single oral administration of 150 mg/kg of
artesunate.
Results and Discussion
The mean AUC0-t and Tmax values of artesunate were
18,968 ± 8,012.4 ng min/ml and 5.0 ± 0.0 min respective-
ly. The corresponding values for dihydroartemisinin were
74,500 ± 16,806.1 ng min/ml and 37.5 ± 8.7 min respec-
tively. The mean calculated absorption tl/2 was 2.73 +/-
0.85 min for artesunate and 12.49 +/- 2.49 min for dihy-
droartemisinin (see Table and Figure). The elimination tl/
2 could not be calculated due to insufficient data points,
because the study was designed to study the absorption
phase.
In another study in the rat [3] in which oral, intramuscu-
lar and intravenous administration of artesunate in 0.9%
saline were compared, the Tmax after oral administration
of artesunate at 10 mg/kg was 30 minutes. Bioavailability
after oral administration was 29.5 ± 4.6%.
The Tmax of artesunate following oral administration in
published studies in humans varies between an average of
0.25 hr (15 min) [4,5] and 0.66 hr (39.6 min)[6] in
healthy volunteers, and 1.7 hr (ca. 1 hr 42 min) in chil-
dren with falciparum hyperparasitaemia [7]. The calculat-
ed absorption tl/2 of parent compound for two different
formulations of oral artesunate were 0.18+/- 0.16 and
0.16+/-0.16 hr in one study (10.8 and 9.6 min respective-
ly) in healthy volunteers [8]. In another study, the Tmax
was longer in convalescent than acute phase patients (0.5
and 1 hr (30–60 min), following the administration of
200 and 100 mg of artesunate, respectively) [9]. First sam-
pling point was reportedly 0.25 hr (15 min) in two studies
[6,7] and 1 hr in one [8]. Overall, published animal and
healthy volunteers data are in general agreement, and cor-
respond to the Tmax of dihydroartemisinin in this study.
Parameters are modified during malaria infection.
This study shows that parent artesunate reaches its peak
more rapidly than what could be anticipated based on ear-
lier studies that start sampling later. The profiles of parent
compound and metabolite result from a complex equa-
tion dictated by the pH-dependent rates of hydroxylation
of artesunate to dihydroartemisinin, the different rates at
which either compounds are absorbed, and the catalytic
hydroxylation by esterases. Because of the rapid conver-
sion of artesunate to dihydroartemisinin in the stomach,
as compared to artesunate's greater stability in plasma, we
conclude that the early dihydroartemisinin levels result
primarily from the absorption of the metabolite as such.
To our knowledge, there is sufficient data to conclude
whether artesunate and/or dihydroartemisinin are ab-
sorbed, and to what extent, in the stomach with respect to
absorption in the small bowel. This study, plus the in vitro
data, indicate that the rate of hydroxilation in the stomach
(artesunate tl/2 at pH 1.2 = ca. 10 min) is faster than the
transit time in either empty or full stomach. So, the pro-
portional absorption of the two moieties in either the
stomach or the small bowel will likely depend on a variety
of factors affecting transit, acidity and bioavailability of
the formulation used. These equilibria will be developed
in a separate paper.
Sampling times in pharmacokinetic studies in both ani-
mals and humans may need to be adjusted accordingly in
order to adequately describe the absorption phase. Ulti-
mately, for antimalarial effect what matters is the com-
bined bioactivity of parent and metabolites. Our results
do not affect this parameter. Rather, they are of practical
relevance to both a better understanding of artesunate's
Table 1: Pharmacokinetics of artesunate and dihydroartemisinin in rats having received a single dose of artesunate
Drug Cmax (ng/ml) Tmax (min) AUC0-t (ngmin/ml) T1/2 absorption (min)
Artesunate 713.1 ± 233.3 5.0 ± 0.0 18968 ± 8012.4 2.73 +/- 0.85
Dihydroartemisinin 2040.3 ± 650.0 37.5 ± 8.7 74500 ± 16806.1 12.49 +/- 2.49BMC Pharmacology 2001, 1 http://www.biomedcentral.com/1471-2210/1/12
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ADMET (particularly the absorption component thereof)
and the assessment and design of suitable formulations.
Materials and Methods
The drug was administered to five batches of ten male
Spraque-Dawley rats housed in a ventilated room at am-
bient temperature (25°C). The rats were starved overnight
before dosing. The animals used weighed between 200 g
and 250 g. Artesunate was prepared as a suspension (vehi-
cle: 10% Poly-ethylene Glycol 200) and administrated
orally using an appropriate oral dosing needle. The for-
mulations were prepared on the day of dose administra-
tion by suspending a weighed quantity of drug in the
appropriate quantity of vehicle and the suspension was
sonicated for 30 seconds. The formulation was adminis-
tered within 5 minutes of preparation by oral gavage.
Bloods samples (1.5 ml) were drawn by cardiac puncture.
Samples were collected at pre-dose (time 0), and then 0.5,
2, 5, 10, 15, 30, 45, 60 and 120 minutes after administra-
tion. Blood samples were obtained from one rat at each
sampling time point. Animals were anaesthetized using
diethyl ether during the procedure (those animals that
were bled at 0.5 and 2 minutes were anaesthetized prior
to dose administration). The protocol was approved by
the Institution's animal ethics committee.
Plasma samples were extracted into ethanol-water and an-
alysed using an HPLC-ECD (electro-chemical detector) in
a mobile phase of acetonitryl and 0.5 M HCl adjusted to
pH 5.0 as described previously [5].
The calibration curve range was 10 ng/0.5 ml to 800 ng/
0.5 ml; detector linearity for artesunate and dihydroar-
temisinin gave an r>0.999; recovery of artesunate was
Figure 1
Pharmacokinetic profiles of rats receiving a single oral dose of artesunate (n = 5; mean +/- standard deviation).BMC Pharmacology 2001, 1 http://www.biomedcentral.com/1471-2210/1/12
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75.5 ± 4.9% with CV of 6.5%; recovery of dihydroartem-
isinin was 93.1 ± 1.8% with CV of 1.9%.
Peak plasma concentration (Cmax) and time to reach
peak concentration (Tmax) for artesunate and dihydroar-
temisinin are reported as the observed values. The area un-
der the plasma concentration versus time curve (AUC)
from time 0 to time t of artesunate and dihydroartemisi-
nin were calculated by linear trapezoidal summation us-
ing model independent Topfit programme. The
absorption half-live (tl/2) was calculated using model in-
dependent Topfit programme. The matrix used for the
standard curve was plasma, ethanol/water (50:50,v/v)
and deionized water; 0.5 ml plasma and Artemisinin (In-
ternal Standard, 5 µl, 40 ng/µl) were spiked into a silan-
ized test-tube. Appropriate amount of artesunate and
dihydroartemisinin were spiked into the tubes separately
and were diluted to 1 ml with water.
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